Why NantKwest Stock Is Skyrocketing Today
After the company unveiled an exciting progress report at the J.P. Morgan Healthcare Conference, shares of NantKwest (NASDAQ: NK), a clinical-stage biotech that uses natural killer (NK) cells to fight cancer, surged 70% as of 11:19 a.m. EST on Thursday.
NantKwest issued a press release that shared preliminary findings of its phase 1 and 2 trials for multiple tumors that were presented at the healthcare conference earlier this week.
Here is a summary of the key clinical updates:
Source Fool.com
